Immuneering Corporation will present at the Jefferies Global Healthcare Conference on June 5, 2025, discussing their pipeline and strategy.
Quiver AI Summary
Immuneering Corporation, a clinical-stage oncology company focused on developing better therapies for cancer patients, announced that its management team will present at the Jefferies Global Healthcare Conference in New York City on June 5, 2025. Key executives, including CEO Ben Zeskind and CMO Igor Matushansky, will discuss the company's pipeline, platform, and business strategy. The presentation will occur from 8:45 to 9:15 am ET and will be available for live streaming and later access on the company's website. Immuneering’s lead product candidate, IMM-1-104, is currently in a Phase 2a trial targeting advanced solid tumors like pancreatic cancer, and the company also has various early-stage development programs. More information can be found on their website.
Potential Positives
- Participation in the prestigious Jefferies Global Healthcare Conference, enhancing the company's visibility and credibility in the healthcare sector.
- The presentation will feature key executives, demonstrating a strong leadership presence and commitment to engaging with investors.
- Discussion of the company's pipeline and business strategy highlights ongoing development efforts and potential future growth opportunities.
- Webcast of the presentation allows for broader audience engagement and access to information for investors and stakeholders.
Potential Negatives
- While the press release highlights participation in a major healthcare conference, it does not provide any new data or updates regarding the company’s pipeline or the status of its lead product candidate, IMM-1-104, which may indicate a lack of significant progress or results.
- The mention of the company being in a clinical stage with its lead product also raises ongoing concerns about the uncertainties and risks associated with clinical trials, which could affect investor confidence.
- There is no information provided about potential challenges or competitive pressures the company might face, suggesting a lack of transparency that could be viewed negatively by investors and stakeholders.
FAQ
What is the purpose of Immuneering's presentation at the Jefferies Global Healthcare Conference?
Immuneering will discuss its pipeline, platform, and business strategy during the conference.
When will Immuneering present at the conference?
The presentation is scheduled for June 5, 2025, from 8:45 to 9:15 am ET.
Who will be presenting on behalf of Immuneering Corporation?
Key executives include CEO Ben Zeskind, CMO Igor Matushansky, and others from the management team.
How can I access the live presentation from Immuneering?
The presentation will be webcast live and archived on Immuneering’s Investor Relations website.
What is Immuneering's lead product candidate?
Immuneering's lead product candidate is IMM-1-104, an oral therapy for RAS-driven tumors.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IMRX Hedge Fund Activity
We have seen 14 institutional investors add shares of $IMRX stock to their portfolio, and 22 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MARSHALL WACE, LLP added 786,537 shares (+3669.9%) to their portfolio in Q1 2025, for an estimated $1,195,536
- PROSIGHT MANAGEMENT, LP removed 190,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $418,000
- ROCKEFELLER CAPITAL MANAGEMENT L.P. removed 177,377 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $269,613
- PRICE T ROWE ASSOCIATES INC /MD/ removed 108,115 shares (-14.1%) from their portfolio in Q1 2025, for an estimated $164,334
- MILLENNIUM MANAGEMENT LLC removed 79,871 shares (-77.6%) from their portfolio in Q1 2025, for an estimated $121,403
- TD ASSET MANAGEMENT INC removed 79,810 shares (-52.9%) from their portfolio in Q1 2025, for an estimated $121,311
- CORIENT PRIVATE WEALTH LLC removed 63,740 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $96,884
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$IMRX Analyst Ratings
Wall Street analysts have issued reports on $IMRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Oppenheimer issued a "Outperform" rating on 05/07/2025
- Morgan Stanley issued a "Underweight" rating on 12/13/2024
To track analyst ratings and price targets for $IMRX, check out Quiver Quantitative's $IMRX forecast page.
Full Release
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that management will present at the Jefferies Global Healthcare Conference, which is taking place at the Marriott Marquis in New York City from June 4-5, 2025, to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Officer, Igor Matushansky M.D., Chief Medical Officer, Brett Hall, Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.
Format: Company Presentation and 1x1 Investor Meetings
Date/Time: June 5 from 8:45 – 9:15 am ET
The presentation will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation .
About Immuneering Corporation
Immuneering is a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients. The Company’s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK designed to improve tolerability and expand indications to include RAS-driven tumors such as most pancreatic cancers. IMM-1-104 is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com .
Media Contact:
Jenna Urban
[email protected]
Investor Contact:
Laurence Watts
619-916-7620
[email protected]
